-
Oppenheimer Assumes Evommune Inc (EVMN) at Outperform
-
Evommune Inc (EVMN) PT Lowered to $50 at H.C. Wainwright
-
Clear Street Starts Evommune Inc (EVMN) at Buy
-
Leerink Partners Reiterates Outperform Rating on Evommune Inc (EVMN): "we remain encouraged by EVMN’s execution"
-
RBC Capital Starts Evommune Inc (EVMN) at Outperform
-
Evommune Inc (EVMN) PT Raised to $65 at H.C. Wainwright
-
Evommune Inc (EVMN) PT Raised to $55 at Evercore ISI
-
Oppenheimer Starts Evommune Inc (EVMN) at Outperform
-
Raymond James Starts Evommune Inc (EVMN) at Strong Buy
-
H.C. Wainwright Starts Evommune Inc (EVMN) at Buy
-
Leerink Partners Starts Evommune Inc (EVMN) at Outperform
-
Cantor Fitzgerald Starts Evommune Inc (EVMN) at Overweight
-
Evercore ISI Starts Evommune Inc (EVMN) at Outperform
-
William Blair Starts Evommune Inc (EVMN) at Outperform
-
Morgan Stanley Starts Evommune Inc (EVMN) at Overweight
-
Evommune (EVMN) files for 9.375M share IPO at $15-$17/sh
-
Evommune (EVMN) files for proposed NYSE IPO

